
Clarity Pharmaceuticals Ltd (CU6) is a clinical stage radiopharmaceutical company. The company is a global leader in Targeted Copper Theranostics (TCT), developed with their proprietary SAR Technology platform. The group also has a range of products in clinical trials which address both prostate cancer and breast cancer as well as neuroendocrine tumours (NETs) and neuroblastoma of cancer.